PORTFOLIO NEWS ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update March 23, 2021 Read More » RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dematitis March 22, 2021 Read More » Carmot Therapeutics expands leadership team with appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&D March 16, 2021 Read More » Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers March 16, 2021 Read More » RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results March 11, 2021 Read More » Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 9, 2021 Read More » NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results March 4, 2021 Read More » Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress March 2, 2021 Read More » NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer March 2, 2021 Read More » Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease March 1, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update March 23, 2021 Read More »
RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dematitis March 22, 2021 Read More »
Carmot Therapeutics expands leadership team with appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&D March 16, 2021 Read More »
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers March 16, 2021 Read More »
RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results March 11, 2021 Read More »
Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 9, 2021 Read More »
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results March 4, 2021 Read More »
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress March 2, 2021 Read More »
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer March 2, 2021 Read More »
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease March 1, 2021 Read More »
